Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19
Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
Pilot clinical trial, with a marketed drug -natural component of human plasma-, not approved
for this indication, single-center, exploratory, open, randomized, controlled, to study the
efficacy and safety of human Antithrombin in patients with confirmed COVID-19 disease and
criteria high risk to develop SARS.
Phase:
Phase 2
Details
Lead Sponsor:
Maimónides Biomedical Research Institute of Córdoba